- Home
- SRG vs RPID Comparison
SRG vs RPID Comparison
Compare SRG & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- RPID
- Stock Information
- Founded
- SRG 2014
- RPID 2006
- Country
- SRG United States
- RPID United States
- Employees
- SRG N/A
- RPID N/A
- Industry
- SRG Real Estate Investment Trusts
- RPID Medical Specialities
- Sector
- SRG Real Estate
- RPID Health Care
- Exchange
- SRG Nasdaq
- RPID Nasdaq
- Market Cap
- SRG 163.3M
- RPID 138.9M
- IPO Year
- SRG 2015
- RPID 2021
- Fundamental
- Price
- SRG $3.29
- RPID $4.08
- Analyst Decision
- SRG
- RPID Buy
- Analyst Count
- SRG 0
- RPID 1
- Target Price
- SRG N/A
- RPID $8.00
- AVG Volume (30 Days)
- SRG 79.7K
- RPID 83.3K
- Earning Date
- SRG 08-13-2025
- RPID 08-05-2025
- Dividend Yield
- SRG N/A
- RPID N/A
- EPS Growth
- SRG N/A
- RPID N/A
- EPS
- SRG N/A
- RPID N/A
- Revenue
- SRG N/A
- RPID $29,645,000.00
- Revenue This Year
- SRG N/A
- RPID $18.54
- Revenue Next Year
- SRG N/A
- RPID $20.55
- P/E Ratio
- SRG N/A
- RPID N/A
- Revenue Growth
- SRG N/A
- RPID 28.36
- 52 Week Low
- SRG $2.43
- RPID $0.66
- 52 Week High
- SRG $5.25
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- SRG 58.23
- RPID 64.35
- Support Level
- SRG $3.20
- RPID $3.38
- Resistance Level
- SRG $3.36
- RPID $4.50
- Average True Range (ATR)
- SRG 0.14
- RPID 0.25
- MACD
- SRG 0.01
- RPID 0.08
- Stochastic Oscillator
- SRG 68.25
- RPID 69.34
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.